Australian Government: Australian Institute of Health and Welfare METeOR Home Page

Person with cancer—lung cancer immunohistochemistry type, code N[N]

Identifying and definitional attributes

Metadata item type:Help on this termData Element
Short name:Help on this termLung cancer immunohistochemistry
METeOR identifier:Help on this term433027
Registration status:Help on this termHealth, Standard 08/05/2014
Definition:Help on this termThe type of immunohistochemistry stains used to assist in the identification of abnormal cells and hence the diagnosis of a person with cancer, as represented by a code.
Context:Help on this termThis should be collected for people with cancer where pathology data is available.
Data Element Concept:Person with cancer—immunohistochemistry type

Value domain attributes

Representational attributes

Representation class:Help on this termCode
Data type:Help on this termNumber
Format:Help on this termN[N]
Maximum character length:Help on this term2
Permissible values:Help on this term
ValueMeaning
1Thyroid transcription factor-1 (TTF-1)
2Cytokeratin 5 (CK5)
3Cytokeratin 6 (CK6)
4Cytokeratin 7 (CK7)
5Cytokeratin 20 (CK20)
6p53-related transcription factor p63 (p63)
7Napsin
88Other
Supplementary values:Help on this term
97Not applicable-immunohistochemical staining not performed
98Unknown if imunohistochemistry performed
99Immunohistochemistry performed but stains not stated/inadequately described

Collection and usage attributes

Guide for use:Help on this termRecord the code for each immunohistochemical profile obtained to assist in the diagnosis of lung cancer.
Comments:Help on this term

Thyroid transcription factor-1 and cytokeratin 7 and 20 can be useful, in conjunction with tumour morphology and clinical and radiological findings, to help to distinguish between primary and metastatic lung adenocarcinomas.

Cytokeratin 5/6 and p63 immunostaining is used by some pathologists to help to determine whether a tumour is a squamous or non-squamous type.

The majority (about 75%) of primary lung adenocarcinomas are CK7 positive, CK20 negative and TTF-1 positive and Napsin stains are positive in approximately 80% of of primary lung adenocarcinomas.

Source and reference attributes

Submitting organisation:Help on this termCancer Australia
Reference documents:Help on this termRoyal College of Pathologists of Australasia 2010. Lung cancer structured reporting protocol. 1st Edition (Version 1.0). Surry Hills, NSW: Royal College of Pathologists of Australasia

Data element attributes

Collection and usage attributes

Guide for use:Help on this term

Record each immunohistochemical profile obtained to assist in the diagnosis of cancer.

When "other" is recorded, record the immunohistochemistry stain in text in Person with cancer—immunohistochemistry type, text X[49].
Collection methods:Help on this termThis information should be sought from the patient's medical record and may be included as a supplementary report in the original pathology report, or a stand-alone pathology report if a different laboratory performs the test.
Comments:Help on this termImmunohistochemistry may be helpful in some instances for precise histological subclassification of the tumour and the exclusion of metastasis.

Source and reference attributes

Submitting organisation:Help on this termCancer Australia

Relational attributes

Related metadata references:Help on this term

See also Person with cancer—immunohistochemistry type, text X[X(49)] Health, Standard 08/05/2014

Implementation in Data Set Specifications:Help on this term
All attributes +

Lung cancer (clinical) DSS Health, Superseded 14/05/2015

DSS specific attributes +

Lung cancer (clinical) NBPDS Health, Standard 14/05/2015

DSS specific attributes +
My items Help on this term
Download Help on this term